A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks

Josef Smolen1, Peter Nash2, Hasan Tahiri3, Hendrik Schulze-Koops4, Lingnan Li5, Maja Hojin6, Amanda M. Gelliot7, Soyi Liu Leage8, Sreekumar Pillai8, Philip Mease8

Medical University of Vienna, Vienna, Austria, 2School of Medicine, Griffith University, Brisbane, Australia, 3Barts Health, London, United Kingdom, 4Ludwig-Maximilians University of Munich, Munich, Germany, 5Eli Lilly, Indianapolis, USA, 6Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, USA

BACKGROUND
- Ik/Mmda (IXE) is a high affinity monoclonal antibody against interleukin-17A1
- Efficacy and safety of IXE in patients with PsA were extensively evaluated in two phase 3, multicenter, double-blind studies: SPIRIT-P1 (NCT01993239) and SPIRIT-P2 (NCT02235092)
- TNF inhibitors, such as adalimumab (ADA), have long been regarded the gold standard treatment for PsA, while IL-17 inhibition has been repeatedly shown in head-to-head (H2H) trials to have superior efficacy in PsA
- Interim, no results of H2H clinical trials directly comparing different biDMARDs in PsA have been presented

KEY RESULTS
- Ixekizumab (IXE) is a high affinity monoclonal antibody against interleukin-17A1
- Efficacy and safety of IXE in patients with PsA were extensively evaluated in two phase 3 studies
- Week 52
- ADA
- IXE
- Efficacy:
- Treatment-emergent adverse events
- Infections
- Potential anaphylaxis
- Inflammatory bowel disease
- Malignancies
- Depression
- Other Secondary Objectives
- Other Secondary Endpoints
- Safety data
- Note: PASI75 is achieved when the PASI score is ≤ 7.5
- Other Secondary Endpoints at Week 24 and Week 52, NRI
- ≥20%/70% improvement in ACR criteria (ACR20, ACR70)
- ≥20%/70% improvement in Psoriasis Area and Severity Index (PASI)
- ≥20%/70% improvement in Disease Activity Score 28-joint in rheumatoid arthritis (DAS28-30)

CONCLUSIONS
- IXE provided significantly greater simultaneous joint and skin improvement versus ADA as early as week 8 and through week 52
- Safety outcomes for IXE and ADA were consistent with previously established safety profiles for both drugs

KEY RESULTS
- Table 1. Safety Outcomes Through Week 52
- Table 2. Adverse Events of Special Interest Through Week 52
- Other Secondary Endpoints
- Note: Patients with multiple occurrences of the same event are counted only once

REFERENCES
- Menter A et al. JEADV. 2017;31:1686-1692
- Smolen JS et al. Rheumatology Nurses Society - 2020 Annual Meeting; Virtual Meeting; August 5-8, 2020
- Smolen JS et al. 2019; 79:123-131